At AstraZeneca, we think differently about the underlying genetic causes of cancer. Our clinical strategy aims to transform survival by seeking to combat metastatic and resistant disease and providing options to treat early. We are defining new biomarkers and therapeutic targets that cut across multiple tumour types. We are transforming the way people with cancer are diagnosed and treated by looking in new places, beyond traditional classifications and focusing on the properties of a tumour, not just its type.
Introduction to our clinical strategy
Our clinical stratgy is designed to transform survival. We aim to combat cancer at all stages, but we know that the earlier we can detect and address cancer, the closer we may be to better outcomes.
You have selected a link that will take you to a site maintained by a third party who is solely responsible for its contents.
AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit.
Click ‘cancel’ to return to AstraZeneca’s site or ‘continue’ to proceed.
You are about to access AstraZeneca historic archive material. Any reference in these archives to AstraZeneca products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data or safety data. Please refer to your approved national product label (SmPC) for current product information.
I have read this warning and will not be using any of the contained product information for clinical purposes.